Contrasting Cumberland Pharmaceuticals (NASDAQ:CPIX) & Xeris Biopharma (NASDAQ:XERS)

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Cumberland Pharmaceuticals and Xeris Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1	0	0	0	1.00
Xeris Biopharma	1	2	4	0	2.43

Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 30.06%. Given Xeris Biopharma’s stronger consensus rating and higher possible upside, analysts plainly believe Xeris Biopharma is more favorable than Cumberland Pharmaceuticals.

Profitability

This table compares Cumberland Pharmaceuticals and Xeris Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Xeris Biopharma	3.81%	735.00%	3.24%

Earnings & Valuation

This table compares Cumberland Pharmaceuticals and Xeris Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52 million	1.97	-$2.84 million	($0.49)	-11.97
Xeris Biopharma	$291.85 million	4.91	$550,000.00	$0.06	138.40

Xeris Biopharma has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 42.7% of Xeris Biopharma shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Cumberland Pharmaceuticals has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Summary

Xeris Biopharma beats Cumberland Pharmaceuticals on 13 of the 14 factors compared between the two stocks.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.